A short pulse of IL-4 delivered by dcs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice

Molecular Therapy

Volumn 18, Issue 12, 2010, Pages 2112-2120

  Creusot, Rémi J ^a   Chang, Pearl ^a   Healey, Don G ^b   Tcherepanova, Irina Y ^b   Nicolette, Charles A ^b   Fathman, C Garrison ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Argos Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; LENTIVIRUS VECTOR; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG PULSE THERAPY; ELECTROPORATION; FEMALE; GLUCOSE BLOOD LEVEL; HELPER CELL; IMMUNE RESPONSE; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; NONVIRAL GENE DELIVERY SYSTEM; REGULATORY T LYMPHOCYTE; RNA TRANSLATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

MUS;

EID: 78650912749     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.146     Document Type: Article

References (31)

1. Anderson, MS and Bluestone, JA (2005). The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23: 447-485.
2. Shoda, LK, Young, DL, Ramanujan, S, Whiting, CC, Atkinson, MA, Bluestone, JA et al. (2005). A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23: 115-126.
3. Smits, HH, de Jong, EC, Wierenga, EA and Kapsenberg, ML (2005). Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol 26: 123-129.
4. Morelli, AE and Thomson, AW (2007). Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 7: 610-621.
5. Creusot, RJ, Yaghoubi, SS, Chang, P, Chia, J, Contag, CH, Gambhir, SS et al. (2009). Lymphoid-tissue-specifc homing of bone-marrow-derived dendritic cells. Blood 113: 6638-6647.
6. Feili-Hariri, M, Falkner, DH, Gambotto, A, Papworth, GD, Watkins, SC, Robbins, PD et al. (2003). Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum Gene Ther 14: 13-23.
7. Creusot, RJ, Yaghoubi, SS, Kodama, K, Dang, DN, Dang, VH, Breckpot, K et al. (2008). Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. Clin Immunol 127: 176-187.
8. Kim, SH, Kim, S, Evans, CH, Ghivizzani, SC, Oligino, T and Robbins, PD (2001). Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modifed to express IL-4. J Immunol 166: 3499-3505.
9. Morita, Y, Yang, J, Gupta, R, Shimizu, K, Shelden, EA, Endres, J et al. (2001). Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 107: 1275-1284.
10. Michiels, A, Tuyaerts, S, Bonehill, A, Corthals, J, Breckpot, K, Heirman, C et al. (2005). Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 12: 772-782.
11. Van Tendeloo, VF, Ponsaerts, P and Berneman, ZN (2007). mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 9: 423-431.
12. Calderhead, DM, DeBenedette, MA, Ketteringham, H, Gamble, AH, Horvatinovich, JM, Tcherepanova, IY et al. (2008). Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinfammatory CTL response. J Immunother 31: 731-741.
13. Feili-Hariri, M, Flores, RR, Vasquez, AC and Morel, PA (2006). Dendritic cell immunotherapy for autoimmune diabetes. Immunol Res 36: 167-173.
14. Lo, J and Clare-Salzler, MJ (2006). Dendritic cell subsets and type I diabetes: focus upon DC-based therapy. Autoimmun Rev 5: 419-423.
15. Trucco, M and Giannoukakis, N (2007). Immunoregulatory dendritic cells to prevent and reverse new-onset Type 1 diabetes mellitus. Expert Opin Biol Ther 7: 951-963.
16. Besin, G, Gaudreau, S, Ménard, M, Guindi, C, Dupuis, G and Amrani, A (2008). Thymic stromal lymphopoietin and thymic stromal lymphopoietin- conditioned dendritic cells induce regulatory T-cell differentiation and protection of NOD mice against diabetes. Diabetes 57: 2107-2117.
17. Giannoukakis, N, Phillips, B and Trucco, M (2008). Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. Pediatr Diabetes 9(3 Pt 2): 4-13.
18. Kyte, JA, Mu, L, Aamdal, S, Kvalheim, G, Dueland, S, Hauser, M et al. (2006). Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13: 905-918.
19. Van Driessche, A, Van de Velde, AL, Nijs, G, Braeckman, T, Stein, B, De Vries, JM et al. (2009). Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. Cytotherapy 11: 653-668.
20. Schuurhuis, DH, Verdijk, P, Schreibelt, G, Aarntzen, EH, Scharenborg, N, de Boer, A et al. (2009). In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 69: 2927-2934.
21. Routy, JP, Boulassel, MR, Yassine-Diab, B, Nicolette, C, Healey, D, Jain, R et al. (2010). Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 134: 140-147.
22. Dullaers, M, Breckpot, K, Van Meirvenne, S, Bonehill, A, Tuyaerts, S, Michiels, A et al. (2004). Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol Ther 10: 768-779.
23. Sherr, J, Sosenko, J, Skyler, JS and Herold, KC (2008). Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 4: 334-343.
24. + precursors. J Immunol 175: 6107-6116.
25. + T regulatory cells that protects against graft-versus-host disease. Blood 113: 4458-4467.
26. Kodama, K, Butte, AJ, Creusot, RJ, Su, L, Sheng, D, Hartnett, M et al. (2008). Tissue-and age-specifc changes in gene expression during disease induction and progression in NOD mice. Clin Immunol 129: 195-201.
27. + cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. Gene Ther 13: 1027-1036.
28. Bonehill, A, Tuyaerts, S, Van Nuffel, AM, Heirman, C, Bos, TJ, Fostier, K et al. (2008). Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 16: 1170-1180.
29. Ponsaerts, P, Van Tendeloo, VF, Cools, N, Van Driessche, A, Lardon, F, Nijs, G et al. (2002). mRNA-electroporated mature dendritic cells retain transgene expression, phenotypical properties and stimulatory capacity after cryopreservation. Leukemia 16: 1324-1330.
30. Yang, AD, Barro, M, Gorziglia, MI and Patton, JT (2004). Translation enhancer in the 3'-untranslated region of rotavirus gene 6 mRNA promotes expression of the major capsid protein VP6. Arch Virol 149: 303-321.
31. Boczkowski, D, Nair, SK, Nam, JH, Lyerly, HK and Gilboa, E (2000). Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplifed from tumor cells. Cancer Res 60: 1028-1034.